Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Omega Protein Announces Second Quarter 2013 Financial Results

      Omega Protein Corporation Logo. (PRNewsFoto/Omega Protein Corporation) (PRNewsFoto/)

      News provided by

      Omega Protein Corporation

      Aug 06, 2013, 03:58 ET

      Share this article

      Share this article


      HOUSTON, Aug. 6, 2013 /PRNewswire/ -- Omega Protein Corporation (NYSE:OME), a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products, today announced results for the second quarter ended June 30, 2013. 

      (Logo: http://photos.prnewswire.com/prnh/20120717/NE41641LOGO)

      Second Quarter 2013 Highlights

      • Revenues:  $41.8 million for the quarter, compared to $48.9 million in the first quarter and $47.5 million in the 2012 second quarter
      • Gross profit margin:  31.8% for the quarter, an increase from 24.7% in the first quarter and 14.4% in the 2012 second quarter
      • Net income:  Net income of $4.0 million for the quarter, compared to $2.8 million in the first quarter and $2.5 million in the 2012 second quarter
      • Earnings:  Earnings per diluted share of $0.19 for the quarter, compared to $0.14 in the first quarter and $0.13 in the 2012 second quarter
      • Adjusted EBITDA:  $11.8 million for the quarter, compared to $10.0 million in the first quarter and $5.2 million in the 2012 second quarter
      • Growth: Announced plans to double capacity of the Company's dairy protein business

      "We are pleased with the Company's increased earnings in the second quarter as we continued to benefit from better animal nutrition sales prices which helped drive higher revenue per ton and consolidated gross margin expansion versus the comparable period last year," commented Bret Scholtes, Omega Protein's President and Chief Executive Officer. "While 2013 fish catch to date has been below average, we are pleased to see fish oil yields rebound sharply from last year and return to more normal year-to-date levels."

      Mr. Scholtes continued, "We believe we are still in the early stages of capitalizing on our human nutrition growth opportunities with second quarter segment revenue 47% higher than the second quarter last year.  Our investments in human nutrition over the last three years provide us with more control over the manufacturing process, create avenues for organic growth, and allow us to better develop additional value-added products to expand consolidated margins in the long-term.  To this point, today we announced an expansion of our dairy protein production facility, which is expected to double its capacity and expand our dairy product offerings."

      Second Quarter 2013 Results
      The Company's revenues decreased 15% from $48.9 million in the first quarter of 2013 to $41.8 million in the second quarter.  The decrease in revenues was due to a $7.9 million decrease in animal nutrition revenues, which reflected lower sales volumes of 14% for fish meal and 66% for fish oil, partially offset by higher sales prices of 10% for fish meal and 64% for fish oil.  Second quarter 2013 sales volumes were negatively impacted by normal seasonal demand and the timing of contracts.  The increase in fish meal sales prices was primarily due to sales made pursuant to contracts entered into at higher prices, and the increase in fish oil sales prices reflected a significant change in product mix.  Human nutrition revenues increased $0.7 million to $7.3 million in the second quarter compared to $6.6 million in the first quarter.  The increase in human nutrition revenues reflects revenues from Wisconsin Specialty Protein (WSP) for a full quarter, partially offset by lower nutraceutical and tolling revenues.  The composition of revenue by nutritional product line for the second quarter of 2013 was 62% fish meal, 18% fish oil, 16% specialty food and nutraceutical ingredients, and 4% fish solubles and other.  

      Second quarter of 2013 revenues decreased 12% from $47.5 million in the same period last year.  The decrease in revenues was due to an $8.0 million decrease in animal nutrition revenues, partially offset by a $2.3 million, or 47%, increase in human nutrition revenues. The decrease in animal nutrition revenues was primarily due to a decrease in sales volume of 25% and 77% for the Company's fish meal and fish oil, respectively, partially offset by increased sales prices of 30% and 127% for the Company's fish meal and fish oil, respectively.  The increase in human nutrition revenues was primarily due to the Company's acquisition of WSP on February 27, 2013.

      The Company reported gross profit of $13.3 million, or 31.8% as a percentage of revenues, for the second quarter of 2013, versus gross profit of $12.1 million, or 24.7% as a percentage of revenues, for the first quarter of 2013.  The increase in gross profit as a percentage of revenues was primarily due to an increase in gross profit as a percentage of revenues from 26.6% to 33.9% in the animal nutrition segment as a result of higher fish oil and fish meal sales prices.  The human nutrition segment reported gross profit as a percentage of revenues of 22.1% in the second quarter of 2013, an increase from 13.0% in the first quarter.  The increase reflects the February 27, 2013 acquisition of WSP and lower transition costs related to the Company's Chicago-area production facility.

      Second quarter gross profit increased from $6.8 million, or 14.4% as a percentage of revenues, in the second quarter of 2012.  The increase was primarily due to an increase in the animal nutrition segment gross profit as a percentage of revenues from 13.4% to 33.9% as a result of increased fish oil and fish meal sales prices.  The human nutrition segment gross profit decreased slightly from 23.3% to 22.1%, as a percentage of revenues, in the second quarter of 2013.

      Selling, general and administrative expenses for the second quarter decreased $0.4 million to $6.0 million compared to the first quarter of 2013 due primarily to reduced professional expenses related to the acquisition of WSP.  Selling, general and administrative expenses increased from $5.4 million for the second quarter of 2012, primarily as a result of the acquisition of WSP.

      The second quarter of 2013 effective tax rate was 34.7% compared to 33.2% in the first quarter of 2013 and 34.0% in the second quarter of 2012. 

      Net income for the second quarter of 2013 was $4.0 million ($0.19 per diluted share) compared to net income of $2.8 million ($0.14 per diluted share) for the first quarter of 2013 and net income of $2.5 million ($0.13 per diluted share) for the same period last year.  Excluding the impact of the net gain or loss on disposal of certain assets, net income for the first quarter of 2013 would have been $3.1 million ($0.15 per diluted share), and net income for the second quarter of 2012 would have been $0.3 million ($0.01 per diluted share).

      Adjusted EBITDA totaled $11.8 million for the second quarter of 2013, compared to $10.0 million for the first quarter of 2013 and $5.2 million for the same period last year.

      Six Month 2013 Results
      Revenues in the current period increased 2% to $90.7 million compared to revenue of $88.5 million for the six months ended June 30, 2012. The increase in revenues for 2013 was due to a $2.1 million increase in human nutrition revenues and a $0.1 million increase in animal nutrition revenues. The increase in human nutrition revenues was due primarily to the acquisition of WSP on February 27, 2013, which contributed $3.3 million of revenue for the six months ended June 30, 2013. The increase in animal nutrition revenues was primarily due to increased sales prices of 22% and 57% for the Company's fish meal and fish oil, respectively, partially offset by decreased sales volumes of 9% and 47% for the Company's fish meal and fish oil, respectively.

      The Company recorded gross profit of $25.4 million, or 28.0% as a percentage of revenues, for the first six months of 2013, versus gross profit of $15.7 million, or 17.8% as a percentage of revenues, for the first six months of 2012.  The increase in gross profit as a percentage of revenues was primarily due to the increase in sales prices.

      Net income for the six months ended June 30, 2013 was $6.8 million ($0.33 per diluted share) compared to $4.3 million ($0.22 per diluted share) for the same period last year.  Excluding the impact of net gain on disposal of assets, net income for the six months ended June 30, 2012 would have been $1.8 million ($0.09 per diluted share). 

      Adjusted EBITDA, totaled $21.8 million for six months ended June 30, 2013, an increase from $12.4 million for the same period last year.

      Balance Sheet
      The Company's balance sheet remains strong, and stockholders' equity increased $12.3 million to $217.9 million as of June 30, 2013 as compared to December 31, 2012.  Total debt decreased $1.6 million from December 31, 2012 to $25.7 million on June 30, 2013.  The Company's June 30, 2013 cash balance decreased $34.5 million from December 31, 2012 to $21.5 million. This decrease was primarily due to the acquisition of WSP in February 2013, as well as expenditures related to 2013 fishing season, capital spending and debt payments, and was partially offset by the sale of inventory.

      Conference Call
      Omega Protein will host a conference call on its second quarter 2013 financial results at 8:30 a.m., Eastern Time, on Wednesday, August 7, 2013. The Company's senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

      Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com. 

      A webcast replay of the conference call will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 90 days. A telephonic replay of the conference call will be available through August 21, 2013. Domestic listeners can dial (877) 870-5177, and international listeners may dial (858) 384-5517. The replay access code is 417268.

      About Omega Protein
      Omega Protein Corporation (NYSE:OME) is a century old nutritional company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of functional foods, dietary supplements and animal feeds.  Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined omega-3 rich fish oil, specialty proteins and nutraceuticals.

      Forward Looking Statements
      SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like "may," "may not," "believes," "do not believe," "expects," "do not expect," "anticipates," "do not anticipate," "see," "do not see," "should," or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company's operations or the sale of the Company's products; (3) the impact of worldwide supply and demand relationships on prices for the Company's products; (4) the Company's expectations regarding demand and pricing for its products proving to be incorrect; (5) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business and its deferral of inventory sales based on worldwide prices for competing products; (6) the long-term effect of the Deepwater Horizon oil spill on the Company's business, operations and fish catch; (7) the business, operations, potential or prospects for the Company's subsidiaries, Cyvex Nutrition, Inc., InCon Processing, LLC, Wisconsin Specialty Protein, LLC, the dietary supplement market or the human health and wellness segment generally; (8) the cost of compliance with existing and future government regulations and (9)   the impact of the Company's  settlement with the U.S Attorney's Office on the Company's operations and financial results. Other factors are described in further detail in the Company's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K.



      OMEGA PROTEIN CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

      (Dollars in thousands)










      June 30, 2013


      December 31,

      2012

      ASSETS







       Current assets:







                Cash and cash equivalents


      $

      21,458


      $

      55,998

                Receivables, net



      21,186



      17,267

                Inventories



      83,344



      66,659

                Deferred tax asset, net



      298



      1,165

                Prepaid expenses and other current assets



      4,844



      3,430








                      Total current assets



      131,130



      144,519

      Other assets, net



      4,300



      10,789

      Property, plant and equipment, net



      144,762



      127,640

      Goodwill



      19,128



      7,986

      Other intangible assets, net



      9,005



      4,362

                      Total assets


      $

      308,325


      $

      295,296








      LIABILITIES AND STOCKHOLDERS' EQUITY














      Current liabilities:







               Current maturities of long-term debt


      $

      3,025


      $

      3,058

               Current portion of capital lease obligation



      121



      268

               Accounts payable



      3,435



      3,000

               Accrued liabilities



      29,083



      31,741

                    Total current liabilities



      35,664



      38,067

      Long-term debt, net of current maturities



      22,706



      24,242

      Capital lease obligation, net of current portion



      4,884



      —

      Deferred tax liability, net



      16,279



      15,794

      Pension liabilities, net



      9,078



      9,826

      Other long-term liabilities



      1,794



      1,764

                      Total liabilities



      90,405



      89,693








      Commitments and contingencies







      Stockholders' equity:







              Preferred stock, $0.01 par value; 10,000,000 authorized shares; none issued                                    



      —



      —

              Common Stock, $0.01 par value; 80,000,000 authorized shares; 20,595,610 and 19,883,940 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively



      201



      195

              Capital in excess of par value



      134,120



      129,040

              Retained earnings



      93,127



      86,292

              Accumulated other comprehensive loss



      (9,528)



      (9,924)

                      Total stockholders' equity



      217,920



      205,603

                          Total liabilities and stockholders' equity


      $

      308,325


      $

      295,296

















      OMEGA PROTEIN CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

      (In thousands, except per share amounts)



      Three Months Ended


      Six Months Ended



      June 30,


      June 30,



      2013


      2012


      2013


      2012

      Revenues

      $

      41,777

      $

      47,448

      $

      90,700

      $

      88,536

      Cost of sales


      28,494


      40,601


      65,320


      72,797

      Gross profit


      13,283


      6,847


      25,380


      15,739










      Selling, general, and administrative expense


      6,030


      5,443


      12,473


      10,728

      Research and development expense


      565


      518


      1,120


      1,119

      Charges related to U.S. Attorney investigation


      —


      70


      —


      303

      Loss (gain) on disposal of assets


      (2)


      (3,385)


      374


      (3,782)

      Operating income


      6,690


      4,201


      11,413


      7,371

      Interest income


      2


      3


      10


      10

      Interest expense


      (481)


      (301)


      (873)


      (697)

      Other expense, net


      (98)


      (102)


      (181)


      (188)

      Income before income taxes


      6,113


      3,801


      10,369


      6,496










      Provision for income taxes


      2,123


      1,291


      3,534


      2,156

      Net income


      3,990


      2,510


      6,835


      4,340










      Other comprehensive income (loss):









      Energy swap adjustment, net of tax benefit of

      $195, $556, $56 and $162, respectively


      (363)


      (1,031)


      (106)


      (300)

      Pension benefits adjustment, net of tax expense of $135, $132, $270 and $265, respectively


      251


      245


      502


      492

      Comprehensive income

      $

      3,878

      $

      1,724

      $

      7,231

      $

      4,532










      Basic earnings per share

      $

      0.20

      $

      0.13

      $

      0.34

      $

      0.22










      Weighted average common shares outstanding


      20,225


      19,613


      20,061


      19,604










      Diluted earnings per share

      $

      0.19

      $

      0.13

      $

      0.33

      $

      0.22










      Weighted average common shares and potential

        common share equivalents outstanding


      21,027


      20,019


      20,837


      20,049










                                                                                                                             

      OMEGA PROTEIN CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

      (Dollars in thousands)












      Six Months Ended

      June 30,






      2013


      2012




      Cash flows from operating activities:








             Net income

      $

      6,835

      $

      4,340




             Adjustments to reconcile net income to net

                cash provided by operating activities:








              Depreciation and amortization


      10,253


      8,798




              Loss (gain) on disposal of assets


      374


      (3,782)




              Provisions for losses on receivables


      24


      24




              Share based compensation


      891


      1,796




              Deferred income taxes


      1,409


      1,531




              Changes in assets and liabilities:








                       Receivables


      (2,671)


      (12,819)




                       Inventories


      (15,763)


      (18,653)




                       Prepaid expenses and other current assets


      (1,515)


      (5,497)




                       Other assets


      5,874


      (3,652)




                       Accounts payable


      (301)


      (354)




                       Accrued liabilities


      (2,873)


      11,349




                       Pension liability, net


      (246)


      (511)




                       Other long term liabilities


      30


      62




                               Net cash provided by (used in) operating

                                   activities


      2,321


      (17,368)




      Cash flows from investing activities:








              Proceeds from disposition of assets


      161


      5,811




              Acquisition of InCon, purchase price adjustment


      —


      181




              Acquisition of Wisconsin Specialty Protein, net of

                  cash acquired


      (26,779)


      —




              Capital expenditures


      (12,560)


      (16,510)




                               Net cash used in

                                 investing activities


      (39,178)


      (10,518)




      Cash flows from financing activities:








              Principal payments of long-term debt


      (1,569)


      (1,469)




              Principal payments of capital lease obligation


      (309)


      (243)




              Debt issuance costs


      —


      (389)




              Proceeds from stock options exercised


      3,048


      437




              Excess tax benefit of stock options exercised


      1,147


      34




                              Net cash provided by (used in)

                                financing activities


      2,317


      (1,630)




      Net decrease in cash and cash equivalents


      (34,540)


      (29,516)




      Cash and cash equivalents at beginning of year


      55,998


      51,391




      Cash and cash equivalents at end of period

      $

      21,458

      $

      21,875













      The tables below present information about reported segments for the three months ended June 30, 2013 and 2012 (in thousands).

      June 30, 2013


      Animal Nutrition


      Human Nutrition(1)


      Unallocated


      Total

      Revenue(2)


      $   34,453


      $  7,324


        $        ―


      $   41,777

      Cost of sales


      22,786


      5,708


                  ―


      28,494

      Gross profit


      11,667


      1,616


                  ―


      13,283

      Selling, general and administrative expenses

        (including research and development)


      662


      1,861


      4,072


      6,595

      Other (gains) and losses


      (2)


      ―


                  ―


      (2)

      Operating income


      $  11,007


      $     (245)


      $   (4,072)


      $     6,690

      Depreciation and amortization


      $     4,472


      $      632


      $        172


      $     5,276

      Identifiable assets


      $ 248,656


      $ 58,125


      $     1,544


      $ 308,325

      Capital expenditures


      $     5,741


      $      324


      $        119


      $     6,184










      (1) Includes revenues and related expenses for WSP.

      (2) Excludes revenue from internal customers of $0.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      June 30, 2012


      Animal Nutrition


      Human Nutrition


      Unallocated


      Total

      Revenue(3)


      $  42,467


      $    4,981


         $    ―


      $   47,448

      Cost of sales


      36,782


      3,819


      ―


      40,601

      Gross profit


      5,685


      1,162


      ―


      6,847

      Selling, general and administrative expenses

        (including research and development)


      556


      927


      4,478


      5,961

      Charges related to U.S. Attorney investigation


      70


      ―


      ―


      70

      Other (gains) and losses


      (3,385)


      ―


      ―


      (3,385)

      Operating income


      $    8,444


      $      235


      $   (4,478)


      $     4,201

      Depreciation and amortization


      $    4,018


      $      319


      $       134


      $     4,471

      Identifiable assets


      $263,276


      $ 27,690


      $    1,786


      $ 292,752

      Capital expenditures


      $    7,260


      $      685


      $       249


      $     8,194










      (3) Excludes revenue from internal customers of $0.2 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      The tables below present information about reported segments for the six months ended June 30, 2013 and 2012 (in thousands).

      June 30, 2013


      Animal Nutrition


      Human Nutrition(1)


      Unallocated


      Total

      Revenue(2)


      $   76,790


      $  13,910


        $        ―


      $   90,700

      Cost of sales


      53,880


      11,440


                  ―


      65,320

      Gross profit


      22,910


      2,470


                  ―


      25,380

      Selling, general and administrative expenses

        (including research and development)


      1,290


      3,157


      9,146


      13,593

      Other (gains) and losses


      374


      ―


      ―


      374

      Operating income


      $  21,246


      $      (687)


      $   (9,146)


      $   11,413

      Depreciation and amortization


      $     8,821


      $   1,070


      $        362


      $   10,253

      Identifiable assets


      $ 248,656


      $ 58,125


      $     1,544


      $ 308,325

      Capital expenditures


      $   11,709


      $      613


      $        238


      $   12,560










      (1) Includes revenues and related expenses for WSP from February 27, 2013 through June 30, 2013.

      (2) Excludes revenue from internal customers of $1.0 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      June 30, 2012


      Animal Nutrition


      Human Nutrition


      Unallocated


      Total

      Revenue(3)


      $  76,706


      $  11,830


         $        ―


      $   88,536

      Cost of sales


      63,880


      8,917


                ―


      72,797

      Gross profit


      12,826


      2,913


                ―


      15,739

      Selling, general and administrative expenses

        (including research and development)


      1,278


      1,921


      8,648


      11,847

      Charges related to U.S. Attorney investigation


      303


                 ―


                 ―


      303

      Other (gains) and losses


      (3,782)


                 ―


                 ―


      (3,782)

      Operating income


      $  15,027


      $      992


      $   (8,648)


      $     7,371

      Depreciation and amortization


      $    7,883


      $      638


      $       277


      $     8,798

      Identifiable assets


      $263,276


      $ 27,690


      $    1,786


      $ 292,752

      Capital expenditures


      $  14,895


      $   1,326


      $       289


      $   16,510










      (3) Excludes revenue from internal customers of $0.5 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      Adjusted EBITDA to Net Income (Loss) Reconciliation
      The following table provides a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended June 30, 2013, March 31, 2013 and June 30, 2012:



      Three Months Ended (in thousands)




      June 30, 2013


      March 31, 2013


      June 30, 2012


      Net Income

      $

      3,990

      $

      2,845

      $

      2,510


      Reconciling items:








         Interest expense


      451


      361


      270


         Income tax provision


      2,123


      1,411


      1,291


         Depreciation and amortization


      5,276


      4,977


      4,471


         Charges related to U.S. Attorney investigation


      ―


      ―


      70


         Net gain or loss on disposal of assets


      (2)


      376


      (3,385)


      Adjusted EBITDA

      $

      11,838

      $

      9,970

      $

      5,227





      Six Months Ended (in thousands)





      June 30, 2013


      June 30, 2012


      Net Income


      $

      6,835

      $

      4,340


      Reconciling items:







         Interest expense



      812


      624


         Income tax provision



      3,534


      2,156


         Depreciation and amortization



      10,253


      8,798


         Charges related to U.S. Attorney investigation



                   ―


      303


         Net gain or loss on disposal of assets



      374


      (3,782)


      Adjusted EBITDA


      $

      21,808

      $

      12,439


      Adjusted EBITDA represents net income (loss) before interest expense, income tax, depreciation and amortization, charges related to U.S. Attorney investigation and net (gain) loss on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income (loss) in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital growth, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income (loss) as defined by GAAP and such information should not be considered as an alternative to net income (loss), cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

      SOURCE Omega Protein Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.